Dr. Gregory M. Sullivan M.D. Net Worth

The estimated Net Worth of Gregory M Sullivan is at least $679 Thousand dollars as of 17 August 2020. Dr Sullivan owns over 20,000 units of Tonix Pharmaceuticals Corp stock worth over $3,211 and over the last 10 years he sold TNXP stock worth over $0. In addition, he makes $676,200 as Chief Medical Officer & Sec. at Tonix Pharmaceuticals Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr D TNXP stock SEC Form 4 insiders trading

Dr has made over 7 trades of the Tonix Pharmaceuticals Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of TNXP stock worth $20,600 on 17 August 2020.

The largest trade he's ever made was buying 20,000 units of Tonix Pharmaceuticals Corp stock on 17 August 2020 worth over $20,600. On average, Dr trades about 4,009 units every 90 days since 2014. As of 17 August 2020 he still owns at least 21,405 units of Tonix Pharmaceuticals Corp stock.

You can see the complete history of Dr Sullivan stock trades at the bottom of the page.

Dr. Gregory M. Sullivan M.D. biography

Dr. Gregory M. Sullivan M.D. is the Chief Medical Officer & Sec. at Tonix Pharmaceuticals Corp.

What is the salary of Dr D?

As the Chief Medical Officer & Sec. of Tonix Pharmaceuticals Corp, the total compensation of Dr D at Tonix Pharmaceuticals Corp is $676,200. There are 3 executives at Tonix Pharmaceuticals Corp getting paid more, with Seth Lederman having the highest compensation of $1,288,270.

How old is Dr D?

Dr D is 55, he's been the Chief Medical Officer & Sec. of Tonix Pharmaceuticals Corp since . There are 11 older and 4 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.

What's Dr D's mailing address?

Gregory's mailing address filed with the SEC is 509 Madison Ave #306, New York, NY 10022, USA.

Insiders trading at Tonix Pharmaceuticals Corp

Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman, and Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.

What does Tonix Pharmaceuticals Corp do?

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

Complete history of Dr Sullivan stock trades at Tonix Pharmaceuticals Corp

Tonix Pharmaceuticals Corp executives and stock owners

Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Seth Lederman,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Seth Lederman M.D.,
  Co-Founder, Pres, CEO & Chairman
• Dr. Seth Lederman,
  Co-Founder, Pres, CEO & Chairman
• Dr. Gregory M. Sullivan M.D.,
  Chief Medical Officer & Sec.
• Gregory Sullivan,
  Secretary, Chief Medical Officer
• Bradley Saenger CPA, CPA,
  CFO & Treasurer
• Bradley Saenger,
  Chief Financial Officer, Treasurer
• Richard Bagger,
  Director
• Herbert Harris,
  Executive Vice President - Translational Medicine
• David Grange,
  Independent Director
• Margaret Bell,
  Independent Director
• James Treco,
  Lead Independent Director
• Adeoye Olukotun,
  Independent Director
• Daniel Goodman,
  Independent Director
• Jessica Morris,
  Chief Operating Officer
• Dr. Sina Bavari Ph.D.,
  Exec. VP of Infectious Disease R&D
• Dr. Anthony Macaluso Ph.D.,
  Exec. VP of Strategic Devel.
• Dr. Darryl Rideout Ph.D.,
  Exec. VP of Experimental Chemistry
• Siobhan Fogarty B.Sc., M.Sc.,
  Exec. VP of Product Devel.
• Dr. Bruce L. Daugherty M.B.A., Ph.D.,
  Exec. VP of Research
• Dr. Herbert W. Harris M.D., Ph.D.,
  Exec. VP of Translational Medicine
• Dr. R. Michael Gendreau,
  Consultant
• Dr. Daniel J. Clauw M.D.,
  Consultant
• Dr. Ronald R. Notvest,
  Exec. VP of Commercial Planning and Devel.
• Jessica Edgar Morris,
  Chief Operating Officer
• Charles E Iv Mather,
  Director
• Ernest Mario,
  Director
• John B Rhodes,
  Director
• Samuel R Saks,
  Director
• Patrick P Grace,
  Director
• Bruce Daugherty,
  See Remarks
• Stuart Davidson,
  Director
• Donald J Kellerman,
  See Remarks
• Leland Gershell,
  CFO and Treasurer
• Carolyn E. Taylor,
  Director
• Richard Newcomb Stillwell,
  Director